170 related articles for article (PubMed ID: 14675593)
1. Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Antonini-Canterin F; Zuppiroli A; Popescu BA; Granata G; Cervesato E; Piazza R; Pavan D; Nicolosi GL
Am J Cardiol; 2003 Dec; 92(12):1479-82. PubMed ID: 14675593
[TBL] [Abstract][Full Text] [Related]
2. Statins and aortic stenosis progression: are biologic targets still an option?
Pai RG
Curr Cardiol Rep; 2005 Nov; 7(6):399-400. PubMed ID: 16256007
[No Abstract] [Full Text] [Related]
3. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Novaro GM; Tiong IY; Pearce GL; Lauer MS; Sprecher DL; Griffin BP
Circulation; 2001 Oct; 104(18):2205-9. PubMed ID: 11684632
[TBL] [Abstract][Full Text] [Related]
4. Do statins slow the process of calcification of aortic tissue valves?
Gilmanov D; Bevilacqua S; Mazzone A; Glauber M
Interact Cardiovasc Thorac Surg; 2010 Sep; 11(3):297-301. PubMed ID: 20570976
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves.
Briand M; Pibarot P; Després JP; Voisine P; Dumesnil JG; Dagenais F; Mathieu P
Circulation; 2006 Jul; 114(1 Suppl):I512-7. PubMed ID: 16820629
[TBL] [Abstract][Full Text] [Related]
6. Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless.
Paraskevas KI; Mikhailidis DP
Interact Cardiovasc Thorac Surg; 2010 Sep; 11(3):302. PubMed ID: 20719912
[No Abstract] [Full Text] [Related]
7. Degeneration of native and tissue prosthetic valve in aortic position: do statins play an effective role in prevention?
Colli A; Gherli T; Mestres CA; Pomar JL
Int J Cardiol; 2007 Mar; 116(2):144-52. PubMed ID: 16828903
[TBL] [Abstract][Full Text] [Related]
8. Detection and Prediction of Bioprosthetic Aortic Valve Degeneration.
Cartlidge TRG; Doris MK; Sellers SL; Pawade TA; White AC; Pessotto R; Kwiecinski J; Fletcher A; Alcaide C; Lucatelli C; Densem C; Rudd JHF; van Beek EJR; Tavares A; Virmani R; Berman D; Leipsic JA; Newby DE; Dweck MR
J Am Coll Cardiol; 2019 Mar; 73(10):1107-1119. PubMed ID: 30871693
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial.
Panahi Y; Sahebkar A; Taghipour HR; Dadjou Y; Pishgoo B; Rakhshankhah AS
Clin Lab; 2013; 59(3-4):299-305. PubMed ID: 23724618
[TBL] [Abstract][Full Text] [Related]
10. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Dichtl W; Alber HF; Feuchtner GM; Hintringer F; Reinthaler M; Bartel T; Süssenbacher A; Grander W; Ulmer H; Pachinger O; Müller S
Am J Cardiol; 2008 Sep; 102(6):743-8. PubMed ID: 18774000
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Are statins effective in preventing bioprosthetic aortic valve failure? A need for a prospective, randomized trial.
Antonini-Canterin F; Popescu BA; Zuppiroli A; Nicolosi GL
Ital Heart J; 2004 Feb; 5(2):85-8. PubMed ID: 15086137
[No Abstract] [Full Text] [Related]
13. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
14. Dose-related effect of statins on atrial fibrillation after cardiac surgery.
Kourliouros A; De Souza A; Roberts N; Marciniak A; Tsiouris A; Valencia O; Camm J; Jahangiri M
Ann Thorac Surg; 2008 May; 85(5):1515-20. PubMed ID: 18442529
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
16. Bioprosthetic valve degeneration due to cholesterol deposition in a patient with normal lipid profile.
Price L; Sniderman A; Omerglu A; Lachapelle K
Can J Cardiol; 2007 Mar; 23(3):233-4. PubMed ID: 17347697
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter aortic valve implantation with a Sapien 3 Commander 20 mm valves in patients with degenerated 19 mm bioprosthetic aortic valve.
Loyalka P; Nascimbene A; Schechter M; Petrovic M; Sundara Raman A; Gregoric ID; Kar B
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1280-1285. PubMed ID: 27696659
[TBL] [Abstract][Full Text] [Related]
18. Valve-in-valve transcatheter aortic valve implantation overcoming hostile anatomy: Evolut R for the treatment of Mitroflow bioprosthesis dysfunction.
Ruparelia N; Colombo A; Latib A
Cardiovasc Interv Ther; 2016 Oct; 31(4):292-5. PubMed ID: 26371364
[TBL] [Abstract][Full Text] [Related]
19. Is there a role of statins in the prevention of aortic biological prostheses degeneration.
Antonini-Canterin F; Zuppiroli A; Baldessin F; Popescu BA; Nicolosi GL
Cardiovasc Ultrasound; 2006 Jun; 4():26. PubMed ID: 16805917
[TBL] [Abstract][Full Text] [Related]
20. Transfemoral valve-in-valve implantation for degenerated bioprosthetic aortic valves using the new balloon-expandable Edwards Sapien 3 valve.
Gonska B; Seeger J; Rodewald C; Scharnbeck D; Rottbauer W; Wöhrle J
Catheter Cardiovasc Interv; 2016 Oct; 88(4):636-643. PubMed ID: 27142354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
